FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015444321> ?p ?o ?g. }

• W2015444321 endingPage "97" @default.
• W2015444321 startingPage "89" @default.
• W2015444321 abstract "In the pathogenesis of doxorubicin (DXR)-induced cardiomyopathy, oxidative stress appears to play an important role. It has been reported that pentosidine and N(epsilon)-(carboxymethyl)lysine (CML), advanced glycation end-products (AGEs), are formed by the combined processes of glycation and oxidation and play a significant role in the process of complications of diabetic mellitus. We investigated the potential involvement of AGE formation in DXR-induced cardiomyopathy in rats. Male Crl:CD(SD) rats received intravenous injection of DXR at 2mg/kg or saline once weekly for 8 weeks, with or without daily treatment with the AGE formation inhibitors, aminoguanidine (AG, 25 mg/kg/day, i.p.) and pyridoxamine (PM, 60 mg/kg/day, i.p.). Time-course experiments revealed significantly increased pentosidine and CML in the heart in the DXR group from Week 6. These findings coincided with a decrease in fractional shortening (FS), an index of cardiac function, and the development of cardiomyopathy characterized by vacuolated hypertrophic myocardial fibers. There was a significant correlation between the myocardial AGEs and FS or plasma cardiac troponin-I. Immunohistochemical staining showed localization of pentosidine to the cytoplasm of vacuolated myocardial cells. In DXR-treated rats, oxidative stress was enhanced prior to any observed increase in pentosidine and CML levels in the heart. Hyperglycemia was not observed throughout the study period. Intervention by AG or PM treatment ameliorated the functional and morphological changes induced by DXR in the heart, in addition to lowered myocardial pentosidine and CML levels. These results suggested that DXR accelerates the formation of pentosidine and CML in the heart through enhanced oxidative stress and that AGE formation is involved in DXR-induced cardiomyopathy. The findings may enable development of novel preventive therapies and predictive biomarkers of DXR-induced cardiomyopathy." @default.
• W2015444321 created "2016-06-24" @default.
• W2015444321 creator A5018014207 @default.
• W2015444321 creator A5018099802 @default.
• W2015444321 creator A5019674030 @default.
• W2015444321 creator A5069643858 @default.
• W2015444321 creator A5091682048 @default.
• W2015444321 date "2010-01-01" @default.
• W2015444321 modified "2023-09-26" @default.
• W2015444321 title "Involvement of advanced glycation end-products, pentosidine and Nɛ-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats" @default.
• W2015444321 cites W1590457525 @default.
• W2015444321 cites W191793640 @default.
• W2015444321 cites W1940436875 @default.
• W2015444321 cites W1977029462 @default.
• W2015444321 cites W1981345102 @default.
• W2015444321 cites W1987416247 @default.
• W2015444321 cites W1987593270 @default.
• W2015444321 cites W1989949137 @default.
• W2015444321 cites W1995716465 @default.
• W2015444321 cites W1996423501 @default.
• W2015444321 cites W1997773121 @default.
• W2015444321 cites W1998614770 @default.
• W2015444321 cites W2008826807 @default.
• W2015444321 cites W2012361366 @default.
• W2015444321 cites W2012486062 @default.
• W2015444321 cites W2012960886 @default.
• W2015444321 cites W2028221313 @default.
• W2015444321 cites W2035437519 @default.
• W2015444321 cites W2045846314 @default.
• W2015444321 cites W2051372789 @default.
• W2015444321 cites W2052393874 @default.
• W2015444321 cites W2060818864 @default.
• W2015444321 cites W2064361198 @default.
• W2015444321 cites W2064901107 @default.
• W2015444321 cites W2069196164 @default.
• W2015444321 cites W2079048926 @default.
• W2015444321 cites W2084321439 @default.
• W2015444321 cites W2085560662 @default.
• W2015444321 cites W2086321305 @default.
• W2015444321 cites W2099514866 @default.
• W2015444321 cites W2118519973 @default.
• W2015444321 cites W2123032423 @default.
• W2015444321 cites W2125216663 @default.
• W2015444321 cites W2133203149 @default.
• W2015444321 cites W2135991691 @default.
• W2015444321 cites W2145124208 @default.
• W2015444321 cites W2147752413 @default.
• W2015444321 cites W2147777431 @default.
• W2015444321 cites W2149987040 @default.
• W2015444321 cites W2160496529 @default.
• W2015444321 cites W2921356930 @default.
• W2015444321 doi "https://doi.org/10.1016/j.tox.2009.12.004" @default.
• W2015444321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20004697" @default.
• W2015444321 hasPublicationYear "2010" @default.
• W2015444321 type Work @default.
• W2015444321 sameAs 2015444321 @default.
• W2015444321 citedByCount "16" @default.
• W2015444321 countsByYear W20154443212012 @default.
• W2015444321 countsByYear W20154443212013 @default.
• W2015444321 countsByYear W20154443212014 @default.
• W2015444321 countsByYear W20154443212015 @default.
• W2015444321 countsByYear W20154443212016 @default.
• W2015444321 countsByYear W20154443212017 @default.
• W2015444321 countsByYear W20154443212018 @default.
• W2015444321 countsByYear W20154443212019 @default.
• W2015444321 countsByYear W20154443212020 @default.
• W2015444321 countsByYear W20154443212022 @default.
• W2015444321 crossrefType "journal-article" @default.
• W2015444321 hasAuthorship W2015444321A5018014207 @default.
• W2015444321 hasAuthorship W2015444321A5018099802 @default.
• W2015444321 hasAuthorship W2015444321A5019674030 @default.
• W2015444321 hasAuthorship W2015444321A5069643858 @default.
• W2015444321 hasAuthorship W2015444321A5091682048 @default.
• W2015444321 hasConcept C111566952 @default.
• W2015444321 hasConcept C126322002 @default.
• W2015444321 hasConcept C134018914 @default.
• W2015444321 hasConcept C147990577 @default.
• W2015444321 hasConcept C185592680 @default.
• W2015444321 hasConcept C2776151105 @default.
• W2015444321 hasConcept C2776553924 @default.
• W2015444321 hasConcept C2776997535 @default.
• W2015444321 hasConcept C2778198053 @default.
• W2015444321 hasConcept C2778797674 @default.
• W2015444321 hasConcept C2780758796 @default.
• W2015444321 hasConcept C2780942790 @default.
• W2015444321 hasConcept C3018763269 @default.
• W2015444321 hasConcept C555293320 @default.
• W2015444321 hasConcept C71924100 @default.
• W2015444321 hasConceptScore W2015444321C111566952 @default.
• W2015444321 hasConceptScore W2015444321C126322002 @default.
• W2015444321 hasConceptScore W2015444321C134018914 @default.
• W2015444321 hasConceptScore W2015444321C147990577 @default.
• W2015444321 hasConceptScore W2015444321C185592680 @default.
• W2015444321 hasConceptScore W2015444321C2776151105 @default.
• W2015444321 hasConceptScore W2015444321C2776553924 @default.
• W2015444321 hasConceptScore W2015444321C2776997535 @default.
• W2015444321 hasConceptScore W2015444321C2778198053 @default.
• W2015444321 hasConceptScore W2015444321C2778797674 @default.

• next